Page 105 - 88_01

ANALES Professionals: Valdecoxib (marketed as Bextra). Center for Drug
RANF Evaluation and Research [Internet]. Disponible en:
https://wayback.archive-
www.analesranf.com it.org/7993/20170112170800/http://www.fda.gov/Safety/Med
Watch/SafetyInformation/Safety AlertsforHumanMedicalPro-
S, et al.. COX-2- selective inhibitors and the risk of upper gastroin- ducts/ucm150752.htm. [Accedido el 16 Jul 2021]
testinal bleeding in high-risk patients with previous gastrointestinal 140. Colditz GA, Miller JN, Mosteller F. How study design affects outcomes
diseases: a population-based case-control study. Aliment Pharmacol in comparisons of therapy. I: Medical. Stat Med. 1989;8(4):441–
Ther. 2004;19(7):817–25. 54.
129. Qadeer MA, Richter JE, Brotman DJ. Hospital-acquired gastrointes-
tinal bleeding outside the critical care unit: risk factors, role of acid Si desea citar nuestro artículo:
suppression, and endoscopy findings. J Hosp Med. 2006;1(1):13– Análisis y evaluación del riesgo cardiovascular y gastrointestinal
20.
130. Ruigomez A, Johansson S, Nagy P, Martin-Perez M, Garcia Rodriguez de los antiinflamatorios no esteroideos inhibidores selectivos y
LA. Risk of uncomplicated peptic ulcer disease in a cohort of new no selectivos de ciclooxigenasa
users of low-dose acetylsalicylic acid for secondary prevention of Antonio Margo
cardiovascular events. Bmc Gastroenterol. 2014;14:1–10. An Real Acad Farm [Internet].
131. Sirois C, Moisan J, Poirier P, Grégoire J-P. Myocardial infarction
and gastro-intestinal bleeding risks associated with aspirin use An. Real Acad. Farm.Vol. 88. nº 1 (2022) · pp 85-103
among elderly individuals with type 2 diabetes. Ann Med. DOI: http://dx.doi.org/10.53519/analesranf.2022.88.01.05
2014;46(5):335–40.
132. Tata LJ, Fortun PJ, Hubbard RB, Smeeth L, Hawkey CJ, Smith CJP,
et al.. Does concurrent prescription of selective serotonin reuptake
inhibitors and non-steroidal anti-inflammatory drugs substantially
increase the risk of upper gastrointestinal bleeding? Aliment Phar-
macol Ther. 2005;22(3):175–81.
133. Tseng CL, Chen YT, Huang CJ, Luo JC, Peng YL, Huang DF, et al..
Short-term use of glucocorticoids and risk of peptic ulcer bleeding:
A nationwide population-based case- crossover study. Aliment Phar-
macol Ther. 2015;42(5):599–606.
134. Wessinger S, Kaplan M, Choi L, Williams M, Lau C, Sharp L, et al..
Increased use of selective serotonin reuptake inhibitors in patients
admitted with gastrointestinal haemorrhage: A multicentre retros-
pective analysis. Aliment Pharmacol Ther. 2006;23(7):937–44.
135. Castellsague J, Riera-Guardia N, Calingaert B, Varas-Lorenzo C, Fou-
rrier-Reglat A, Nicotra F, et al. Individual NSAIDs and Upper
Gastrointestinal Complications. Drug Saf. 2012;35(12):1127–
46.
136. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono
C. Do selective cyclo- oxygenase-2 inhibitors and traditional non-
steroidal anti-inflammatory drugs increase the risk of atherothrom-
bosis? Meta-analysis of randomised trials. BMJ. 2006;332:1302.
137. Massó González EL, Patrignani P, Tacconelli S, García Rodríguez LA.
Variability among nonsteroidal antiinflammatory drugs in risk of
upper gastrointestinal bleeding. Arthritis Rheum.
2010;62(6):1592–601.
138. Varas-Lorenzo C, Riera-Guardia N, Calingaert B, Castellsague J, Pa-
riente A, Scotti L, et al. Stroke risk and NSAIDs: a systematic review
of observational studies. Pharmacoepidemiol Drug Saf.
2011;20:1225–36.
139. U.S. Food and Drug Administration. Postmarket Drug Safety Infor-
mation for Patients and Providers - Information for Healthcare

Análisis y evaluación del riesgo cardiovascular y gastrointestinal de los antiinfla- 103
matorios no esteroideos inhibidores selectivos y no selectivos de ciclooxigenasa

Antonio Margo

An. Real Acad. Farm.Vol. 88. nº 1 (2022) · pp. 85-103